Literature DB >> 21711467

A randomized comparison of excimer laser versus narrow-band ultraviolet B phototherapy after punch grafting in stable vitiligo patients.

M W Linthorst Homan1, Ph I Spuls, L Nieuweboer-Krobotova, J de Korte, M A G Sprangers, J D Bos, A Wolkerstorfer, J P W van der Veen.   

Abstract

Background  Ultraviolet radiation following punch grafting may stimulate the migration of melanocytes from the grafts into the vitiliginous skin, thereby increasing the rate of repigmentation. We compared the effects of the 308-nm xenon chloride excimer laser (EL) vs. narrow-band ultraviolet B (NB-UVB) after punch grafting in patients with vitiligo. Objectives  The aims of this study were to evaluate (i) repigmentation (%); (ii) treatment satisfaction; and (iii) patient preferences for EL vs. NB-UVB therapy after punch grafting in vitiligo. Methods  Fourteen patients were treated with the punch-grafting technique on two symmetrical vitiligo patches. Starting 1 week after the punch grafting, the vitiligo patches were treated twice a week during 3 months, with EL on one side and with NB-UVB on the other side. Repigmentation (%) was measured by a digital image analysis system. Patients' satisfaction and preference for treatment were also assessed. Results  Whereas both treatment modalities induced repigmentation, no statistically significant difference was found in grade of repigmentation after 3 months. With EL, 71.4% lower cumulative dose was reached. Patients were significantly more satisfied with NB-UVB and preferred it over EL. Conclusions  The choice between EL and NB-UVB cannot solely be based on repigmentation, but rather on other factors, such as patients' preferences. However, given the lower UV dose of EL, we recommend its use in vulnerable populations, such as in small children and patients with sun-damaged skin with a history of long-term UVB treatment.
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2011        PMID: 21711467     DOI: 10.1111/j.1468-3083.2011.04147.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  8 in total

Review 1.  Advances in Vitiligo: An Update on Medical and Surgical Treatments.

Authors:  Alexander B Dillon; Andrew Sideris; Ali Hadi; Nada Elbuluk
Journal:  J Clin Aesthet Dermatol       Date:  2017-01-01

2.  Comparison Between (311-312 nm) Narrow Band Ultraviolet-B Phototherapy and (308 nm) Monochromatic Excimer Light Phototherapy in Treatment of Vitiligo: A Histopathological Study.

Authors:  Manal Mohamed Salah Eldin; Nevein Ahmed Sami; Dalia Gamal Aly; Noha Sami Hanafy
Journal:  J Lasers Med Sci       Date:  2017-06-27

Review 3.  [The 308 nm Excimer laser : Treatment of vitiligo and hypopigmentation].

Authors:  K Fritz; C Salavastru
Journal:  Hautarzt       Date:  2018-01       Impact factor: 0.751

Review 4.  Effectiveness of a 308-nm excimer laser in treatment of vitiligo: a review.

Authors:  Alauldin Khalef Alhowaish; Nathalie Dietrich; Meltem Onder; Klaus Fritz
Journal:  Lasers Med Sci       Date:  2012-08-15       Impact factor: 3.161

Review 5.  Current Management of Pediatric Vitiligo.

Authors:  Freya Van Driessche; Nanette Silverberg
Journal:  Paediatr Drugs       Date:  2015-08       Impact factor: 3.022

Review 6.  Grafting in vitiligo: how to get better results and how to avoid complications.

Authors:  Imran Majid
Journal:  J Cutan Aesthet Surg       Date:  2013-04

7.  A comparative study for the short-term effects of targeted high-intensity UVB and narrow-band UVB in the treatment of vitiligo.

Authors:  Min Zhang; Wei-Yuan Ma
Journal:  Exp Ther Med       Date:  2017-04-26       Impact factor: 2.447

Review 8.  The use of lasers in vitiligo, an overview.

Authors:  N F Post; N Ezekwe; V S Narayan; M W Bekkenk; N Van Geel; I Hamzavi; T Passeron; A Wolkerstorfer
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-03-01       Impact factor: 9.228

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.